| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/18/2010 | WO2009033715A3 Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases |
| 03/18/2010 | WO2008139313A8 Propofol transparent anaesthetic solution with low venous irritation |
| 03/18/2010 | US20100069814 System and method for utilizing microbubbles and liposomes as viral sequestering agents |
| 03/18/2010 | US20100069509 Nonionic emulsifiers for emulsion concentrates for spontaneous emulsification |
| 03/18/2010 | US20100069397 Sexual dysfunction compounds |
| 03/18/2010 | US20100069342 Formoterol/steroid bronchodilating compositions and methods of use thereof |
| 03/18/2010 | US20100068311 Preparation, process and a regenerative method and technique for prevention, treatment and glycemic control of diabetes mellitus |
| 03/18/2010 | US20100068291 Oral Medicament Based on a Proton Pump Inhibitor |
| 03/18/2010 | US20100068290 Coated pellets |
| 03/18/2010 | US20100068289 Spherical microcapsules comprising glp-i peptides, their production and use |
| 03/18/2010 | US20100068288 Mixtures or organic compounds for the treatment of airway diseases |
| 03/18/2010 | US20100068287 Process for Preparation of a Stable Dispersion of Solid Amorphous Submicron Particles in an Aqueous Medium |
| 03/18/2010 | US20100068286 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same |
| 03/18/2010 | US20100068285 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same |
| 03/18/2010 | US20100068284 Stable Fixed Dose Topical Formulation |
| 03/18/2010 | US20100068283 Ex VIVO modifiable particle or polymeric material medicament carrier |
| 03/18/2010 | US20100068282 Preparation of pharmaceutical compositions |
| 03/18/2010 | US20100068281 Methods and compositions for tissue regeneration |
| 03/18/2010 | US20100068280 Sustained release pharmaceutical dosage form containing phenylephrine |
| 03/18/2010 | US20100068279 Burn bandage |
| 03/18/2010 | US20100068278 Ex vivo modifiable medicament release-associations |
| 03/18/2010 | US20100068277 Ex vivo modifiable multiple medicament final dosage form |
| 03/18/2010 | US20100068276 Multiparticulates of spray-coated drug and polymer on a meltable core |
| 03/18/2010 | US20100068275 Personalizable dosage form |
| 03/18/2010 | US20100068274 Process for production of tablet |
| 03/18/2010 | US20100068273 Pharmaceutical formulation, its use, and method for its manufacture |
| 03/18/2010 | US20100068272 Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors |
| 03/18/2010 | US20100068271 Divisible Osmotic Dosage Forms and Methods of Use |
| 03/18/2010 | US20100068270 Bupropion hydrobromide polymorphs |
| 03/18/2010 | US20100068269 Treatment and prevention of cardiovascular events |
| 03/18/2010 | US20100068268 Starch-based microparticles for the release of agents disposed therein |
| 03/18/2010 | US20100068267 Compositions for treating vascular diseases characterized by nitric oxide insufficiency |
| 03/18/2010 | US20100068266 Ex vivo-modifiable multiple-release state final dosage form |
| 03/18/2010 | US20100068265 Gelatin capsules comprising an acid |
| 03/18/2010 | US20100068264 Niosome-hydrogel drug delivery system |
| 03/18/2010 | US20100068263 Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen |
| 03/18/2010 | US20100068262 Method and Compositions for Stimulation of an Immune Response to PSMA using a Xenogeneic PSMA Antigen |
| 03/18/2010 | US20100068261 Methods and compositions for the production of monoclonal antibodies |
| 03/18/2010 | US20100068260 Methods, Compositions and Device for Directed and Controlled Heating and Release of Agents |
| 03/18/2010 | US20100068259 Natural product inhibitors of 3dg |
| 03/18/2010 | US20100068258 Prophylactic tuberculosis vaccine |
| 03/18/2010 | US20100068257 Sustained Release of Antiinfectives |
| 03/18/2010 | US20100068256 Ex vivo modifiable medicament release-substance |
| 03/18/2010 | US20100068255 liposomes comprising humanized Fab fragment of monoclonal antibody that binds cell surface markers, amphipathic vesicle-forming lipid and polyethylene glycol derivatized lipid, capable of inhibiting growth and proliferation of target cells; HER growth factor receptors |
| 03/18/2010 | US20100068254 Modifying a medicament availability state of a final dosage form |
| 03/18/2010 | US20100068253 Bleomycin preparation for use against skin tumours |
| 03/18/2010 | US20100068252 Method for preparing polymeric matrices by radiation in the presence of sensitive pharmaceutical compounds |
| 03/18/2010 | US20100068251 Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof |
| 03/18/2010 | US20100068250 Abuse Potential Reduction in Abusable Substance Dosage Form |
| 03/18/2010 | US20100068249 Abuse-resistant transdermal dosage form |
| 03/18/2010 | US20100068248 Patch and patch preparation |
| 03/18/2010 | US20100068247 Method And System For Providing Targeted And Individualized Delivery Of Cosmetic Actives |
| 03/18/2010 | US20100068246 Process for Providing a Quantity of a Particulate Material, Product and Apparatus |
| 03/18/2010 | US20100068245 Preparation and storage of stable, biologically active materials |
| 03/18/2010 | US20100068244 Stabilized biodegradable neurotoxin implants |
| 03/18/2010 | US20100068243 Macroporous and highly resorbable apatitic calcium-phosphate cement |
| 03/18/2010 | US20100068241 Reconstituted mineralized cartilage tissue |
| 03/18/2010 | US20100068239 Osteogenic Device for Inducing Bone Formation in Clinical Contexts |
| 03/18/2010 | US20100068235 Individualizable dosage form |
| 03/18/2010 | US20100068234 Laser-Markable Compositions |
| 03/18/2010 | US20100068233 Modifiable dosage form |
| 03/18/2010 | US20100068220 Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby |
| 03/18/2010 | US20100068196 Method of micronization |
| 03/18/2010 | US20100068156 Ampholytic copolymer based on quaternized nitrogen-containing monomers |
| 03/18/2010 | US20100068155 Reactant Formulations and Methods for Controlled Heating |
| 03/18/2010 | US20100068154 Printable Igniters |
| 03/18/2010 | US20100068153 Ex vivo activatable final dosage form |
| 03/18/2010 | US20100068152 Ex vivo modifiable particle or polymeric based final dosage form |
| 03/18/2010 | US20100065445 Pre-Packaged, Customized, Woven, Wet Towel |
| 03/18/2010 | CA2773755A1 Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
| 03/18/2010 | CA2737247A1 Starch-based microparticles for the release of agents disposed therein |
| 03/18/2010 | CA2736833A1 Vinyl alcohol co-polymer cryogels, vinyl alcohol co-polymers, and methods and products thereof |
| 03/18/2010 | CA2736812A1 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion |
| 03/18/2010 | CA2736780A1 Solvent extraction microencapsulation with tunable extraction rates |
| 03/18/2010 | CA2736547A1 Method for delivering a pharmaceutical composition to patient in need thereof |
| 03/18/2010 | CA2736317A1 Apparatus and method for dehydrating biological materials with freezing and microwaving |
| 03/18/2010 | CA2736210A1 Systems and methods for modeling of crystallization processes |
| 03/18/2010 | CA2735660A1 Dosage forms for weakly ionizable compounds |
| 03/18/2010 | CA2734381A1 Improvements in the absorption of therapeutic agents across mucosal membranes or the skin |
| 03/18/2010 | CA2734309A1 Preparation and usage of a pharmaceutical composition containing ferulic acid and matrine compounds |
| 03/18/2010 | CA2734189A1 Treatment of acute myocardial infarction (ami) using encapsulated cells encoding and secreting glp-1 peptides or analogs thereof |
| 03/18/2010 | CA2731321A1 Compositions for percutaneous administration |
| 03/18/2010 | CA2730561A1 Modified release ramipril compositions and uses thereof |
| 03/17/2010 | EP2163626A1 Human FGF-21 gene and gene expression products |
| 03/17/2010 | EP2163548A1 Prophylactic or therapeutic agent for age-related macular degeneration |
| 03/17/2010 | EP2163249A1 Infusion solution for peripheral intravenous administration |
| 03/17/2010 | EP2163243A1 Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof |
| 03/17/2010 | EP2163242A1 Capsule with soluble blocking element |
| 03/17/2010 | EP2163241A1 Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| 03/17/2010 | EP2163240A1 A method for the production of bioadhesive compact matrices |
| 03/17/2010 | EP2163239A1 Products containing bioparticles, method for their manufacture |
| 03/17/2010 | EP2162283A2 Self assembled films for protein and drug delivery applications |
| 03/17/2010 | EP2162154A1 Colored esmolol concentrate |
| 03/17/2010 | EP2162142A2 Acellular tissue matrix compositions for tissue repair |
| 03/17/2010 | EP2162141A1 Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue |
| 03/17/2010 | EP2162128A1 Sesquiterpene formulations, kits and methods of use thereof |
| 03/17/2010 | EP2162126A2 Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine |
| 03/17/2010 | EP2162123A1 Honokiol analogs and their use in treating cancers |
| 03/17/2010 | EP2162122A1 Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof |
| 03/17/2010 | EP2162121A2 Method for coating surfaces with micro- and nanoparticles with the aid of plasma methods |